STAT3 inhibitor. Blocks spherogenesis of cancer stem cells (CSC), but not hematopoietic stem cells. Inhibits PaCa-2 xenograft tumor growth in mice, even after cessation of treatment, and decreases population of CSCs in PaCa-2 tumors from treated mice. Also blocks spleen and liver metastases of colon cancer cells in a mouse model.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 240.21. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||4.16 mL||20.82 mL||41.63 mL|
|5 mM||0.83 mL||4.16 mL||8.33 mL|
|10 mM||0.42 mL||2.08 mL||4.16 mL|
|50 mM||0.08 mL||0.42 mL||0.83 mL|
References are publications that support the products' biological activity.
Li et al (2015) Suppression of cancer relapse and metastasis by inhibiting cancer stemness. Proc.Natl.Acad.Sci.USA. 112 1839 PMID: 25605917
If you know of a relevant reference for Napabucasin, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Napabucasin, supplier, Stat3, inhibitors, inhibits, cancer, stem, cell, stemness, high, self-renewal, spherogenesis, metastasis, STAT, Stem, Cell, Signaling, Cancer, Stem, Cells, STAT, Tocris Bioscience
Citations for Napabucasin
Citations are publications that use Tocris products.
Currently there are no citations for Napabucasin. Do you know of a great paper that uses Napabucasin from Tocris? If so please let us know.
Average Rating:(Based on 0 Reviews)